By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies today said that it and partner Asuragen have achieved CE marking and launched in Europe their BCR/ABL1 Quant Test, which is used to monitor treatment of chronic myeloid leukemia patients. Asuragen manufactures the test, and Life Technologies exclusively distributes the test, which runs on the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.